Effectiveness of baricitinib in severe alopecia areata in real life

This study assessed the effectiveness and safety of baricitinib, an oral JAK inhibitor, in treating severe alopecia areata (AA) over a 52-week period. Involving 87 patients with a mean age of 29.84 years, the study found that 37.20% of participants achieved a Severity of Alopecia Tool (SALT) score of ≤ 20, indicating significant hair regrowth. The mean baseline SALT score was 77.07%, and a significant reduction in scores was observed by the end of the study (p < 0.001). Additionally, 72.40% of patients experienced mild or no adverse events, with no serious adverse events reported. The findings suggest that baricitinib is both effective and well-tolerated for long-term management of severe AA.